Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SPRINT.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.30
vs -0.19
Q1.23
N/A
-0.18
vs -0.30
Q2.23
N/A
-0.17
vs -0.38
Q3.23
+248%
0.41
vs -0.28
Q4.23
N/A
-0.07
vs -0.30
Q1.24
N/A
-0.04
vs -0.18
Q2.24
N/A
-0.08
vs -0.17
Q3.24
N/A
-0.07
vs 0.41
Q4.24
N/A
-0.06
vs -0.07
Q1.25
N/A
-0.08
vs -0.04
Sales Growth
YoY
Current
Estimates
Q4.22
-98%
14K vs 731K
Q1.23
-100%
NA vs 45K
Q2.23
+128%
41K vs 18K
Q3.23
+791220%
39.6M vs 5K
Q4.23
+77600%
10.9M vs 14K
Q1.24
NA
17.9M vs NA
Q2.24
+40629%
16.7M vs 41K
Q3.24
-63%
14.8M vs 39.6M
Q4.24
+50%
16.3M vs 10.9M
Q1.25
-21%
14.1M vs 17.9M
Return on Equity
QoQ
Q2.23
-279%
-2.79
vs -0.77
Q3.23
+87%
0.87
vs -2.79
Q4.23
-18%
-0.18
vs 0.87
Q1.24
-12%
-0.12
vs -0.18
Q2.24
-31%
-0.31
vs -0.12
Q3.24
-39%
-0.39
vs -0.31
Q4.24
-45%
-0.45
vs -0.39
Q1.25
-155%
-1.55
vs -0.45
Institutionnal Ownership
Quote Panel
Key Metrics
Forecast
1169%2026-Revenue
603%2026-EPS
-2234%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
SPRINT.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
STO
Unprofitable
Unprofitable
-0.02Â ( -3.85%)
Relative Strenght
Volume Buzz
-86%
Earning Acce
No
Dist 52w H.
78%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SPRINT.ST compares to sector?